Table 2 Characteristics of the whole study population

Age category

≤ 40 years

44

35.8%

> 40 years

79

64.2%

ACR grade

Grade A

4

3.3%

Grade B

45

36.6%

Grade C

68

55.3%

Grade D

6

4.9%

Number of lesions by SMG

Nil

6

4.9%

Single lesion

96

78.0%

2 lesions

12

9.8%

3 lesions

5

4.1%

4 lesions

4

3.3%

BIRADS class by SMG

BIRADS1

7

5.7%

BIRADS 2

0

0.0%

BIRADS 3

23

18.7%

BIRADS 4

40

32.5%

BIRADS 5

4

3.3%

BIRADS 6

49

39.8%

Indication for CESM

Follow-up of neo-adjuvant chemotherapy

25

20.3%

Mass in dense breast

8

6.5%

Staging of breast cancer

23

18.7%

Suspicious lesion on mammography with no US correlate

17

13.8%

Focal asymmetry

24

19.5%

Postoperative follow-up

12

9.8%

Parenchymal distortion

13

10.6%

Suspicious palpable lesion

1

0.8%

Number of lesions by CESM

Nil

22

17.9%

Single lesion

61

49.6%

2 lesions

12

9.8%

3 lesions

22

17.9%

4 lesions

5

4.1%

5 lesions

1

0.8%

Grade of enhancement

No enhancement

24

19.5%

Minimal

12

9.8%

Mild

11

8.9%

Moderate

14

11.4%

Marked

62

50.4%

BIRADS class by CESM

BIRADS 2

29

23.6%

BIRADS 3

2

1.6%

BIRADS 4

37

30.1%

BIRADS 5

8

6.5%

BIRADS 6

47

38.2%

Pathological type and course

Adenosis

3

2.4%

Atypical ductal hyperplasia

3

2.4%

Benign postoperative changes

5

4.1%

Complete response

8

6.5%

Cyst

4

3.3%

DCIS

11

8.9%

Fat necrosis

3

2.4%

Fibroadenoma

5

4.1%

Fibrocystic changes

3

2.4%

Granulomatous mastitis

4

3.3%

Hamartoma

1

0.8%

IDC

18

14.6%

IDC within in-situ component

11

8.9%

ILC

13

10.6%

IMLN

2

1.6%

Infected cyst

1

0.8%

Lipoma

1

0.8%

Minimal residual disease

5

4.1%

Mucinous carcinoma

2

1.6%

Papilloma

2

1.6%

Partial response

2

1.6%

Recurrent IDC

4

3.3%

Stationary disease

12

9.8%

Reference index

Follow-up

13

10.6%

Needle aspiration

5

4.1%

Tru-Cut biopsy

55

44.7%

Surgical biopsy

49

39.8%

Stereotactic biopsy

1

0.8%

Final diagnosis

Benign

37

30.1%

Malignant

86

69.9%